FGF9 and ovarian carcinoma: In ovarian cancer, circITGB6 promotes an M2 macrophage‐dependent cisplatin resistance by forming a circITGB6/IGF2BP2/FGF9 RNA‐protein ternary complex by directly interacting with IGF2BP2 and FGF9 mRNA, which stabilize FGF9 mRNA and induce polarization of TAMs toward M2 phenotype.349